Related Experiment Videos
GSK3β genetic variability in patients with Multiple Sclerosis.
Daniela Galimberti1, James Macmurray, Diego Scalabrini
1Department of Neurological Sciences, "Dino Ferrari" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy. daniela.galimberti@unimi.it
Neuroscience Letters
|April 30, 2011
Summary
Genetic variations in Glycogen synthase kinase-3 beta (GSK3β) were studied in multiple sclerosis (MS). A specific GSK3β variant (rs334558 GG) was found to increase MS susceptibility, particularly in the Relapsing Remitting subtype.
Area of Science:
- Neuroscience
- Genetics
- Immunology
Background:
- Glycogen synthase kinase-3 beta (GSK3β) plays a role in neuroprotection and energy metabolism.
- GSK3β is implicated in Wnt-beta-catenin signaling, affecting myelination and remyelination processes.
- Dysregulation of GSK3β signaling is potentially linked to neurological disorders like multiple sclerosis (MS).
Purpose of the Study:
- To investigate the association between common Glycogen synthase kinase-3 beta (GSK3β) variants and susceptibility to multiple sclerosis (MS).
- To determine if specific GSK3β genotypes influence MS risk or disease subtypes.
Main Methods:
- Genotyping of 319 MS patients and 294 controls for four common GSK3β variants (rs2199503, rs9826659, rs334558, rs6438552).
- Allelic discrimination method used for genotyping.
- Statistical analysis to compare genotype frequencies between MS patients and controls, including stratification by MS subtype.
Main Results:
- A statistically significant increase in the rs334558 GG genotype frequency was observed in MS patients compared to controls (25.4% vs. 17.7%, P=0.02).
- This association remained significant when stratifying by MS subtype, with a higher frequency of the rs334558 GG genotype in Relapsing Remitting MS patients (27.0% vs. 17.7%, P=0.01).
- The rs334558 variant, located in the promoter region, may influence gene transcription rates.
Conclusions:
- The GSK3β rs334558 variant is identified as a susceptibility factor for multiple sclerosis.
- This genetic variation may contribute to MS pathogenesis, potentially through altered GSK3β gene expression.
- Further research is warranted to elucidate the precise mechanisms linking GSK3β variants to MS development.
Related Concept Videos
02:26Comparing Copy Number Variations and SNPs
Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:25Genetic Variation
Genetic variation is the diversity in DNA sequences found among individuals of the same species. This diversity is crucial for a species' survival because it helps organisms adapt to environmental changes. Genetic variation begins with fertilization, where an egg and sperm cell merge. Each of these cells carries 23 chromosomes, up to 46 in the fertilized egg. Chromosomes are long DNA strands that contain genes, the basic units of heredity.
Genes exist in different versions called alleles, which...
Genes exist in different versions called alleles, which...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...